Holly Hagan1, Hanne Thiede, Don C Des Jarlais. 1. Center for Drug Use and HIV Research, National Development and Research Institutes, New York, New York 10010, USA. hagan@ndri.org
Abstract
BACKGROUND: Time to hepatitis C virus (HCV) seroconversion in initially seronegative injection drug users has not been directly measured, and public health planning would benefit from specifying the window of opportunity for prevention of infection, and factors that affect timing of infection. METHODS: Four hundred eighty-four HCV antibody-negative injection drug users in Seattle, Washington were followed a median of 2.1 years to observe seroconversion. We examined time to HCV seroconversion in relation to subject characteristics using the Kaplan-Meier method and Cox proportional hazards regression. A weighted-average time to HCV seroconversion was calculated among new injectors (injecting < or = 2 years) using seroprevalence and seroincidence data. RESULTS: There were 134 HCV seroconversions (11.6 per 100 person-years at risk; the 25th percentile of time to seroconversion was 26.2 months). Injection with a syringe used by another injector (adjusted hazards ratio = 1.8; 95% confidence interval = 1.3-3.0) and sharing a cooker or cotton (1.8; 1.0-3.1) were associated with time to HCV seroconversion. Using the estimate of the mean time to seroconversion from first injection in new injectors who were HCV antibody-negative at enrollment (5.4 years), and the midpoint between first injection and study enrollment in new injectors who were HCV antibody-positive at enrollment (0.6 years), the weighted-average time to seroconversion after beginning to inject was estimated to be 3.4 years. CONCLUSION: The period of susceptibility to HCV infection in the majority of drug injectors appears to be long enough to justify the allocation of substantial resources toward interventions to reduce injection-related risk behavior in these individuals.
BACKGROUND: Time to hepatitis C virus (HCV) seroconversion in initially seronegative injection drug users has not been directly measured, and public health planning would benefit from specifying the window of opportunity for prevention of infection, and factors that affect timing of infection. METHODS: Four hundred eighty-four HCV antibody-negative injection drug users in Seattle, Washington were followed a median of 2.1 years to observe seroconversion. We examined time to HCV seroconversion in relation to subject characteristics using the Kaplan-Meier method and Cox proportional hazards regression. A weighted-average time to HCV seroconversion was calculated among new injectors (injecting < or = 2 years) using seroprevalence and seroincidence data. RESULTS: There were 134 HCV seroconversions (11.6 per 100 person-years at risk; the 25th percentile of time to seroconversion was 26.2 months). Injection with a syringe used by another injector (adjusted hazards ratio = 1.8; 95% confidence interval = 1.3-3.0) and sharing a cooker or cotton (1.8; 1.0-3.1) were associated with time to HCV seroconversion. Using the estimate of the mean time to seroconversion from first injection in new injectors who were HCV antibody-negative at enrollment (5.4 years), and the midpoint between first injection and study enrollment in new injectors who were HCV antibody-positive at enrollment (0.6 years), the weighted-average time to seroconversion after beginning to inject was estimated to be 3.4 years. CONCLUSION: The period of susceptibility to HCV infection in the majority of drug injectors appears to be long enough to justify the allocation of substantial resources toward interventions to reduce injection-related risk behavior in these individuals.
Authors: Taraz Samandari; Ellen Tedaldi; Carl Armon; Rachel Hart; Joan S Chmiel; John T Brooks; Kate Buchacz Journal: Open Forum Infect Dis Date: 2017-06-10 Impact factor: 3.835
Authors: Brendan Jacka; Tanya Applegate; Art F Poon; Jayna Raghwani; P Richard Harrigan; Kora DeBeck; M-J Milloy; Mel Krajden; Andrea Olmstead; Jeffrey B Joy; Brandon D L Marshall; Kanna Hayashi; Oliver G Pybus; Viviane Dias Lima; Gkikas Magiorkinis; Julio Montaner; Francois Lamoury; Gregory J Dore; Evan Wood; Jason Grebely Journal: J Hepatol Date: 2016-02-26 Impact factor: 25.083
Authors: William A Zule; Elizabeth C Costenbader; Curtis M Coomes; Wendee M Wechsberg Journal: Am J Public Health Date: 2009-02-12 Impact factor: 9.308
Authors: Jennifer R Havens; Michelle R Lofwall; Simon D W Frost; Carrie B Oser; Carl G Leukefeld; Richard A Crosby Journal: Am J Public Health Date: 2012-11-15 Impact factor: 9.308
Authors: Norah A Terrault; Kelly Im; Ross Boylan; Peter Bacchetti; David E Kleiner; Robert J Fontana; Jay H Hoofnagle; Steven H Belle Journal: Clin Gastroenterol Hepatol Date: 2008-08-19 Impact factor: 11.382
Authors: Kimberly Page-Shafer; Brandee L Pappalardo; Leslie H Tobler; Bruce H Phelps; Brian R Edlin; Andrew R Moss; Teresa L Wright; David J Wright; Thomas R O'Brien; Sally Caglioti; Michael P Busch Journal: J Clin Microbiol Date: 2007-11-21 Impact factor: 5.948